Overview
- Samsung Biologics America signed a definitive agreement to acquire 100% of Human Genome Sciences from GSK, securing the company’s first U.S. manufacturing base.
- The Rockville, Maryland campus includes two cGMP plants with a combined 60,000 liters of drug substance capacity supporting clinical and commercial production.
- Existing production will continue at the site, and Samsung Biologics plans further investment to expand capacity and upgrade technology to bolster U.S. biologics supply resilience.
- GSK said the divestment will secure U.S. manufacture of two key medicines, and Samsung Biologics highlighted future multi‑site options across the U.S. and South Korea for clients.
- Coverage noted the Biosecure Act and trade pressures as context for U.S. onshoring, and reported Samsung Biologics’ shares fell nearly 5% on investor concerns about costs and integration risk.